UPC Issues Cross-European Injunction Finding BioNTech and Pfizer Guilty of Patent Infringement

WISECODE Take

The UPC Hague Local Division's November 10, 2026 ruling finding Pfizer and BioNTech guilty of patent infringement appears to be a sweeping cross-border victory, but it is fundamentally a tactical leverage move pushing opponents to the licensing table. While many businesses assume cross-border patent litigation requires separate lawsuits in each jurisdiction, they overlook the broad reach of the UPC's long-arm jurisdiction. The panel found Pfizer and BioNTech's Comirnaty vaccine infringed GSK's EP 2 590 626 B1 patent claims, extending conditional injunctions across 18 UPCA contracting states and non-UPCA EPC countries like Switzerland and Turkey. The court suspended execution for three months to allow for licensing negotiations before enforcement. This indicates that multinational groups can no longer shelter behind separate local entities, as integrated corporate operations are treated as joint infringement. Companies without European operations or relevant product lines remain unaffected by this ruling. Business leaders should take two key steps: first, review supply chain integration and corporate structures across target markets to identify cross-border liability exposure; second, conduct invalidity assessments on key patents while preparing parallel revocation filings in separate jurisdictions such as the UK High Court. In international patent disputes, victory is rarely about absolute market bans, but about securing favorable licensing terms under the pressure of a conditional injunction.